Immunology Drug Developer Veteran Brian Wipke, Ph.D., Joins Fannin and Allterum Therapeutics

Allterum Therapeutics – January 8, 2026

Advancing Hope for Children with Leukemia: Allterum Therapeutics Receives FDA Fast Track Designation for 4A10 in Acute Lymphoblastic Leukemia

Allterum Therapeutics – November 11, 2025

Hope in Fight Against Pediatric Cancers: Allterum Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Appl. for 4A10 in Acute Lymphoblastic Leukemia

PRWeb – October 9, 2025

Allterum Therapeutics Awarded $1 Million SBIR Grant from NCI to Support Clinical Development of 4A10 in Childhood Leukemia

PRWeb – Sept 9, 2025

Allterum Awarded Third Major CPRIT Grant to Accelerate Therapeutic Development

PRWeb – June 13, 2025

Industry veteran Dr. Yan Moore joins Allterum Therapeutics as CEO to advance clinical program in ALL

Allterum Therapeutics – Jan 6, 2025

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PRWeb – October 7, 2024

Allterum Therapeutics receives $12 million product development grant from CPRIT to advance anti-CD127 therapeutic antibody into clinic

PRWeb – April 8, 2024

Fannin/Allterum awarded $2 million SBIR Phase II grant from NIH to advance monoclonal antibody for treating childhood leukemia

PRNewswire – July 19, 2023

Allterum Therapeutics completes Series Seed offering, builds team with addition of Philip Breitfeld as Chief Medical Officer

PRNewswire – Dec 17, 2020

Allterum Therapeutics granted Orphan Drug Designation and Rare Pediatric Disease Designation for its monoclonal antibody therapy for pediatric leukemia

PRWEB – Oct 6, 2020

.

Allterum Therapeutics closes $2.9 million CPRIT award to develop novel NCI technology for treating pediatric leukemia, initiates drug manufacturing scale-up with FujiFilm Diosynth

PRNewswire – April 21, 2020

Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

NCI at Frederick – March 19, 2019